BGBeatriz Baaklini Geronymo

Beatriz Baaklini Geronymo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Beatriz Baaklini Geronymo has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    2025 São Paulo Breast Symposium Guidelines: luminal breast cancer and axillary surgery

    by Eduardo Carvalho Pessoa, Fabio Bagnoli, Marcelo Madeira, Joaquim Teodoro Araujo, Giuliano Mendes Tosello, Fabricio Brenelli, Beatriz Baaklini Geronymo, Daniel de Araujo Buttros, Felipe Zerwes, Marcelo Antonini, et al.

    Introduction: This study aims to disseminate evidence-based expert consensus statements derived from the 2025 International Symposium on Breast Diseases of Inland São Paulo (SIMIP), addressing four critical areas in breast cancer management: (1) initial treatment strategies for luminal breast cancer with imaging-positive (iN1) and clinically positive axilla (cN1); (2) therapeutic approaches for estrogen receptor–low (ER-low) breast cancer; (3) optimal duration of adjuvant endocrine therapy (ET) in luminal tumors; and (4) criteria for omitting axillary surgery in early breast cancer. Methods: The 2025 São Paulo Breast Diseases Symposium was a two-day event held in São Paulo, Brazil, involving 110 panelists, including 99 mastologists (90%) and 11 professionals from related fields (pathology, breast imaging, radiotherapy, and clinical oncology). Panelists were selected based on recognized expertise, defined by at least 10 years of clinical experience or significant academic contribution. Four priority thematic axes were identified through a pre-symposium survey of Brazilian and South American specialists. Each topic was introduced by a 10-minute evidence-based lecture followed by a 50-minute technical debate. Anonymous electronic voting was conducted via a secure online platform during hybrid sessions, with consensus defined as agreement by ≥75% of participants. Results: For patients with imaging-positive axilla (iN1), 52% of panelists preferred upfront surgery, without reaching consensus. In clinically positive axilla (cN1), treatment choice between upfront surgery and neoadjuvant chemotherapy varied according to age and menopausal status, supported by 57% of voters, also without consensus. A consensus of 84% was achieved to manage ER-low breast cancer similarly to triple-negative disease, using chemotherapy combined with endocrine therapy. Regarding endocrine therapy duration, consensus was reached for 7–10 years in high-risk Luminal B tumors (97%) and for 5 years in low-risk Luminal A tumors (95%). Omission of axillary surgery was supported by 85% of panelists in patients with tumors ≤2 cm, clinically node-negative disease (cT1N0), hormone receptor-positive/HER2-negative tumors, and negative axillary ultrasound findings. Conclusions: These expert consensus statements support personalized, multidisciplinary strategies to optimize oncologic outcomes while minimizing morbidity. Consensus favors extended endocrine therapy for high-risk luminal disease, shorter therapy for low-risk tumors, combined chemotherapy and endocrine therapy for ER-low disease, and omission of axillary surgery in carefully selected early breast cancer cases. Management of iN1 and cN1 disease should remain individualized based on clinical and biological factors, particularly in Brazil, where late-stage presentation remains frequent.

  • Open Access

    2025 International Symposium on Breast Diseases of Inland São Paulo: oncoplastic surgery in breast cancer treatment

    by Eduardo Carvalho Pessoa, Fabio Bagnoli, Marcelo Madeira, Joaquim Teodoro Araujo, Giuliano Mendes Tosello, Fabricio Brenelli, Beatriz Baaklini Geronymo, Daniel de Araujo Buttros, Evandro Fallaci Mateus, Natalie Rios, et al.

    Introduction: Oncoplastic surgery has become an essential component of breast cancer management, aiming to balance oncologic safety with aesthetic outcomes. However, controversies persist regarding its application in specific clinical scenarios, such as multicentric tumors, implant-based reconstruction in the context of adjuvant radiotherapy, and reconstruction after inflammatory breast cancer with optimal response. Methods: This study reports the clinical guidelines established during the 2025 International Symposium on Breast Diseases of Inland São Paulo. A total of 110 panelists participated, including 99 mastologists (90%) and 11 breast cancer–related specialists (pathologists, breast imaging specialists, radiotherapists, and clinical oncologists; 10%). Four priority topics were addressed through evidence-based lectures, followed by structured technical discussions and anonymous electronic voting. Consensus was defined as agreement ≥75%. Results: Sectoriectomy with oncoplastic techniques was preferred for the management of multicentric tumors (65%), although consensus was not achieved. Prepectoral implant-based reconstruction was the most frequently selected option (53%), also without consensus. Consensus was reached regarding the use of definitive implants in patients undergoing adjuvant radiotherapy (80%) and the absence of an absolute contraindication to breast reconstruction in cases of inflammatory breast cancer with optimal response to systemic therapy (84%). Conclusions: These guidelines reflect contemporary oncoplastic practice, emphasizing breast preservation, oncologic safety, and aesthetic outcomes. The use of definitive implants in the setting of adjuvant radiotherapy and breast reconstruction after inflammatory carcinoma with optimal response is supported by consensus. In contrast, the management of multicentric tumors and implant positioning remains individualized, underscoring areas where further prospective research is needed.

  • Open Access

    Clinical Guidelines from the 2025 International Symposium on Breast Diseases of Inland São Paulo: GLP-1 Inhibitors, Risk-Reducing Surgery in BRCA Carriers, Liquid Biopsy, and DCIS Treatment De-escalation

    by Eduardo Carvalho Pessoa, Fabio Bagnoli, Marcelo Madeira, Joaquim Teodoro Araujo, Giuliano Tosello, Fabricio Brenelli, Beatriz Baaklini Geronymo, Daniel de Araujo Buttros, Cesar Cabello, Ana Luisa de Castro Baccarin, et al.

    Introduction: The 2025 International Symposium on Breast Diseases of Inland São Paulo convened to establish consensus on emerging topics in oncology. This study aims to disseminate the clinical guidelines voted on regarding four aspects of breast cancer management: the impact of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) on risk reduction; risk-reducing surgery in breast cancer gene (BRCA) mutation carriers; use of liquid biopsy (circulating tumor DNA [ctDNA]) in metastatic cases; and management of low-grade ductal carcinoma in situ (DCIS). Methods: Four priority topics were presented in evidence-based lectures, followed by technical discussions and anonymous electronic voting by 100 panelists. Consensus was defined as an agreement of ≥75%. Results: No consensus was reached on GLP-1RAs for breast cancer risk reduction (50% in favor, 43% citing inconclusive evidence, 7% against). Risk-reducing surgery in BRCA mutation carriers achieved consensus (92% in favor) as beneficial for survival. Liquid biopsy was recommended for monitoring metastatic cases (74% in favor, just below the consensus threshold). Standard treatment for low-grade DCIS was preferred (84% in favor) over active surveillance (16%). Conclusions: The guidelines highlight the absence of conclusive evidence for GLP-1RAs in breast cancer prevention, the survival benefit of risk-reducing surgery in BRCA carriers, the utility of liquid biopsy in metastatic cases, and the preference for standard treatment in low-grade DCIS to prevent progression. Further studies are needed to address unresolved issues.

  • Open Access

    Triple-negative breast cancer: 2025 consensus guidelines

    by Eduardo Carvalho Pessoa, Fabio Bagnoli, Marcelo Madeira, Joaquim Teodoro Araujo, Giuliano Mendes Tosello, Fabricio Brenelli, Beatriz Baaklini Geronymo, Daniel de Araujo Buttros, Felipe Zerwes, Marcelo Antonini, et al.

    Objective: To disseminate the clinical guidelines established at the 2025 São Paulo Breast Diseases Symposium regarding the management of early triple-negative breast cancer (TNBC). Methods: The symposium convened 110 panelists, predominantly mastologists from São Paulo (101 mastologists, of which 94 from São Paulo and 7 from other regions: 1 from Bahia [Northeast], 2 from Rio Grande do Sul [South], 1 from Minas Gerais, 2 from Goiânia [central region], and 1 from Fortaleza [Northeast]), plus 6 oncologists, 2 pathologists, and 1 radiotherapist (all from São Paulo). Four priority topics were presented in evidence-based lectures, followed by technical discussions and anonymous electronic voting by all panelists. Consensus was defined as ≥75% agreement. Results: Voting showed 40% support for T1cN0 as the cutoff for upfront surgery, 16% for T2N0, but no consensus was reached. Consensus was achieved for using tumor-infiltrating lymphocytes (TILs) as an adjunct biomarker to guide initial systemic treatment (83%) and for sentinel lymph node biopsy (SLNB) as standard following neoadjuvant chemotherapy (NACT) (78%). Post-mastectomy radiotherapy was recommended even after pathological complete response (pCR) by 72%, though without consensus. Conclusions: The 2025 São Paulo Breast Diseases Symposium established guidelines for early TNBC management. Consensus was achieved for using TILs as an adjunct biomarker (83%) and SLNB as standard post-NACT (78%), while upfront surgery cutoff (40% for T1cN0) and radiotherapy omission post-pCR (72%) did not reach consensus, reflecting heterogeneous practices and the need for individualized approaches and further research.

  • Open Access

    Clinical Guidelines from the 2025 International Symposium on Breast Diseases of Inland São Paulo: management of breast cancer in special situations

    by Eduardo Carvalho Pessoa, Fabio Bagnoli, Marcelo Madeira, Joaquim Teodoro Araujo, Giuliano Tosello, Fabricio Brenelli, Beatriz Baaklini Geronymo, Daniel de Araujo Buttros, Lincon Jo Mori, Francisco Pimentel Cavalcante, et al.

    Introduction: The 2025 International Symposium on Breast Diseases of Inland São Paulo addressed clinically relevant controversies in the management of breast cancer in special situations, including inflammatory carcinoma, axillary micrometastases after neoadjuvant chemotherapy, early luminal tumors in elderly women, and the use of vaginal estrogen therapy after breast cancer treatment. Methods: Four priority topics were presented in evidence-based lectures, followed by expert panel discussions and anonymous electronic voting. Consensus was predefined as agreement of at least 75% among panelists. Results: No consensus was reached regarding the use of sentinel lymph node biopsy in inflammatory carcinoma, although 73% of panelists voted against its performance. Likewise, no consensus was achieved on omitting axillary lymph node dissection in patients with axillary micrometastases after neoadjuvant chemotherapy, despite 61% considering this approach feasible. In elderly women with early luminal tumors, the most frequently selected option was to maintain standard treatment (29%), with no consensus supporting treatment de-escalation. In contrast, consensus was reached regarding the safety of vaginal estrogen therapy after breast cancer treatment, with 88% of panelists supporting its use in appropriately selected patients. Conclusions: These guidelines summarize expert-based recommendations for the management of breast cancer in challenging clinical scenarios and reinforce the importance of individualized, multidisciplinary decision-making. Sentinel lymph node biopsy was generally not supported in inflammatory carcinoma, and vaginal estrogen therapy was considered safe in selected breast cancer survivors. Greater caution remains warranted regarding treatment de-escalation in elderly women with early luminal tumors and omission of axillary lymph node dissection in the setting of residual micrometastatic nodal disease after neoadjuvant chemotherapy.

  • Open Access

    Clinical and Public Health Guidelines from the 2025 International symposium on breast diseases of inland São Paulo: strategies for early breast cancer detection and HER2-positive treatment within Brazil’s unified health system

    by Eduardo Carvalho Pessoa, Fabio Bagnoli, Marcelo Madeira, Joaquim Teodoro Araujo, Giuliano Tosello, Beatriz Geronymo, Daniel de Araujo Buttros, André Mattar, Renato Torresan, João Bosco Ramos Borges, et al.

    Objective: To disseminate the clinical and public health policy consensus established during the 2025 International Symposium on Breast Diseases of Inland São Paulo, based on the voting of 110 expert panelists in breast oncology. Methods: Four priority topics were presented through evidence-based lectures, followed by anonymous electronic voting using a validated Delphi-based methodology. Consensus was defined as ≥75% agreement among panelists. Results: Consensus was achieved on prioritizing mammography screening from age 40 (80% agreement) and on the positive impact of interdisciplinary integration in early diagnosis (95% agreement). No consensus was reached on optimizing São Paulo’s High Suspicion Law (67% agreement) or on the tumor size cutoff for neoadjuvant chemotherapy in human epidermal growth factor receptor 2 (HER2)-positive breast cancer, with the majority (53%) favoring tumors >20 mm (T2N0). Conclusion: The symposium’s guidelines provide evidence-based recommendations to enhance breast cancer screening, early diagnosis, and treatment within Brazil’s Unified Health System (SUS). While consensus was reached on earlier screening and interdisciplinary integration, further discussion is needed to optimize the High Suspicion Law and standardize neoadjuvant therapy criteria. These findings have significant potential to improve patient outcomes and resource allocation in the SUS.

  • Open Access

    Consensus from the 2025 International Symposium on Breast Diseases of Inland São Paulo: Management of HER2-Positive Breast Cancer

    by Eduardo Carvalho Pessoa, Fabio Bagnoli, Marcelo Madeira, Joaquim Teodoro Araujo, Giuliano Mendes Tosello, Fabricio Brenelli, Beatriz Baaklini Geronymo, Daniel de Araujo Buttros, Leonardo Fleury Orlandini, Sheila Wludarski, et al.

    Objective: To present the expert panel recommendations derived from the panel discussion “Management of HER2-Positive Breast Cancer”, held during the 2025 International Symposium on Breast Diseases of Inland São Paulo (SIMIP), addressing critical controversies in treatment. Methods: Priority topics were discussed in evidence-based lectures, followed by technical debates and anonymous electronic voting among 110 panelists. Consensus was defined as agreement of ≥75%. Panelists were predominantly mastologists (101), of whom 94 were from São Paulo (Southeast) and seven from other regions: one from Bahia (Northeast), two from Rio Grande do Sul (South), one from Minas Gerais, two from Goiás (Central-West), and one from Ceará (Northeast). The panel also included six oncologists, two pathologists, and one radiotherapist, all from São Paulo. Panelists disclosed no relevant conflicts of interest related to human epidermal growth factor receptor 2 (HER2)-targeted therapies. Lectures were based on selected literature from existing clinical practice guidelines and pivotal clinical trials; no prior systematic review was conducted. The number of respondents varied across questions because voting participation was optional for each item, and the exact number of votes for each question was presented in the respective results tables. The questionnaire consisted of single-choice, forced-response items using binary or categorical formats, depending on the topic (not a Likert scale). The consensus process followed a structured expert panel methodology with anonymous electronic voting, but the number of respondents per question could vary. Results: The majority of respondents (64%) concluded that there is no standardization for HER2-low and ultra-low categories. For adjuvant therapy, 67% defined >5 mm (starting at T1bN0) as the threshold for indication. Neoadjuvant chemotherapy was recommended for tumors ≥2 cm by 68% of specialists. The HER2 genomic/prognosis test (DX) does not significantly alter management, according to 55% of votes. Conclusions: These expert consensus statements reflect current evidence and the majority views of the panel, supporting the management of HER2-positive breast cancer, with emphasis on multidisciplinary evaluation. Standardization of HER2-low and ultra-low categories and the clinical utility of HER2DX require further validation. These statements represent the majority opinion of Brazilian specialists and are intended to support clinical reasoning rather than define mandatory protocols or formal clinical practice guidelines.

  • Open Access

    Clinical Guidelines from the 2025 International Symposium on Breast Diseases of Inland São Paulo: Imaging Assessment and Management of B3 Breast Lesions

    by Eduardo Carvalho Pessoa, Fabio Bagnoli, Marcelo Madeira, Joaquim Teodoro Araujo, Giuliano Tosello, Fabricio Brenelli, Beatriz Geronymo, Daniel de Araujo Buttros, Bruna Salani Mota, Henrique Lima Couto, et al.

    Objective: To establish evidence-based clinical guidelines from the 2025 International Symposium on Breast Diseases of Inland São Paulo (SIMIP 2025), addressing four key axes of breast cancer diagnosis and management: indications for preoperative magnetic resonance imaging (MRI), vacuum-assisted excision (VAE) for B3 lesions (breast lesions of uncertain malignant potential), supplemental imaging for dense breasts, and the preferred imaging modality (contrast-enhanced mammography [CEM] or MRI) for high-risk women. Methods: Each axis was presented in evidence-based lectures, followed by debates and anonymous electronic voting by 100 specialists. Consensus was defined as ≥75% agreement. Results: Preoperative MRI was recommended for selected cases (100% in favor), including invasive lobular carcinoma, dense breasts, and occult carcinoma. VAE for B3 lesions received 98% support, except for phyllodes tumors and papillary lesions with atypia. Supplemental imaging for dense breasts was unanimously endorsed (64% preferred MRI, 36% voted for ultrasound). For high-risk women, MRI was chosen by 100%, with CEM as an alternative. Conclusion: The guidelines reinforce MRI for selected preoperative cases and high-risk screening, emphasize VAE as an effective approach for managing B3 lesions, and advocate for supplemental imaging (preferably MRI) for dense breasts, with multidisciplinary decision-making.